Search

everythinglearnresearchcommunity

for

Search:↓

The user is considering starting pyrilutamide before a scheduled hair transplant, having previously used oral minoxidil and finasteride with worsening results. They also tried dutasteride, which worsened their hair and made their skin oily.

KX-826 may cause increased hair loss for some users, leading to concerns about its effects. One user reported no issues but also no hair regrowth, only maintenance.

A user applied pyrilutamide for 6 months without hair regrowth and is considering stopping due to cost and lack of results. Another user suggests switching to finasteride, which is cheaper and has shown regrowth for them.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.

The conversation is about a hair loss serum mix containing 5% capixyl, 3% redensyl, and procapil. The user is asking for recommendations or opinions on the effectiveness of this product.

Men discussing hair loss treatments, including bicalutamide, cyproterone acetate, dutasteride, minoxidil, and RU58841. They share experiences and concerns about side effects like infertility, liver health, and feminization.

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

A user inquired about Cipla Tugain Men, a topical solution containing Minoxidil 5% and Finasteride 0.1%, noting its less greasy texture and good price. Responses suggest it's similar to other products with the same ingredients, questioning the effectiveness of additional components.

Skin, Hair, and Nails by Pharmekal was withdrawn from the market. Users discuss alternative supplements and treatments like Minoxidil, finasteride, and RU58841.

The user is sharing their progress with hair loss treatments including finasteride, minoxidil, keto shampoo, and dermastamping. Other users are expressing positive reactions and discussing the benefits of keto shampoo and minoxidil.

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.

Pyrilutamide, a potential hair loss treatment that has been tested in Phase 2 trials and may be available for purchase through a group buy in June. It is purported to have similar effects on hair growth as Dutasteride.

User asks about CB-03-01 for hair loss treatment and mentions using topical Dutasteride, TRT, and considering mixing CB-03-01 with Fluridil. CB-03-01 is sold at a high price, and user considers trying a lower concentration.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Taking zinc and copper may offset copper depletion and potentially aid hair health when used with finasteride. The user is considering whether to use these supplements alongside finasteride or wait until switching to dutasteride.

The conversation is about the use and application of CB-03-01-2 (Breezula) for hair loss, including questions about its form, how to apply it, and the duration 10g would last. Specific treatments discussed are Minoxidil, finasteride, and RU58841.

Han Bio claims success in hair multiplication using dermal papilla cells. Treatments discussed include Minoxidil, finasteride, and RU58841.

The user is discussing their hair loss treatment stack, which includes CB-03-01, Fluridil, Alfatradiol, Cosmerna, microneedling, and Stemoxydine. They have seen some new hair growth but wish they could use finasteride.

A 26-year-old is considering switching from a regimen of minoxidil, finasteride, and RU58841 to possibly include pyrilutamide due to insufficient results in slowing hair loss. They are seeking advice on whether to add pyrilutamide or replace RU58841 with it, considering cost and effectiveness.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.

A user is testing clascoterone (Winlevi) on their scalp for hair loss and has noticed a reduction in scalp sebum after one month. They are also using other unspecified treatments and plan to provide an update after the second month.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

Pyrilutamide's long-term stability is uncertain, with potential degradation after 8-9 months if not stored properly. It's recommended to use fresh batches and store them in a cool, dark place.